Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Acacia Pharma Ltd.. (9/3/13). "Press Release: Acacia Pharma Raises £15m ($23.5m) to Advance Clinical Development of Lead Products". Cambridge.

Organisations Organisation Acacia Pharma Ltd.
  Group Acacia Pharma (Group)
  Organisation 2 Fidelity Biosciences
  Today F-Prime Capital Partners (F-Prime Biosciences)
  Group F-Prime Capital Partners (F-Prime Biosciences)
Products Product Baremsis (APD421)
  Product 2 venture capital
Index term Index term Acacia Pharma–SEVERAL: investment, 201309 financing round Series B £15m led by new invesors Fidelity Biosciences + Novo A/S
Persons Person Gilbert, Julian (Acacia Pharma Ltd 201309 CEO)
  Person 2 Edwards, Martin (Novo AS 200902 Senior Partner + Symphogen 200902 Board Chairman)
     


Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Board of Acacia Pharma as Non-executive Directors.

Acacia Pharma will use the proceeds to:

- complete Phase III development of APD421 for the prevention of post-operative nausea & vomiting (PONV);
- complete Phase II development of APD403 for the prevention of chemotherapy induced nausea & vomiting (CINV); and
- develop the commercial presentation of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

"I am delighted to welcome Fidelity Biosciences and Novo to the Company and would like to thank Gilde and Lundbeckfond for their continued support," commented Dr Julian Gilbert, Acacia Pharma's CEO. "The Company is about to initiate a number of key studies with results being available in 2014. The data generated to date in PONV, CINV and xerostomia have been excellent; therefore we look forward to continued success."

Dr Alex Pasteur of Fidelity Biosciences added, "Significant numbers of post-surgical patients do not receive adequate nausea and vomiting prophylaxis. APD421, Acacia Pharma's lead product, a D2/D3 antagonist, showed excellent efficacy in its Phase II trial, and had a very good safety profile. We believe that a drug with this novel mechanism and displaying these characteristics can provide a major contribution to the care of post-surgical patients."

Dr Martin Edwards of Novo A/S stated, "In addition to APD421, Acacia Pharma has generated excellent Phase II a proof-of-concept data on APD403 in CINV. The drug, the same D2/D3 antagonist used in APD421, appears to have a unique anti-nauseant profile and can be added to current recommended CINV regimens due to its novel, complementary, mechanism of action, thereby targeting the key unmet need within this debilitating condition. We have high hopes for APD403 and for the future success of the Company."


Acacia Pharma Ltd, Harston Mill, Harston, Cambridge, CB22 7GG
Tel: +44 (0)1223 875130 Fax: +44 (0)1223 875131
Website by College Hill Life Sciences

   
Record changed: 2018-02-15

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

More documents for Acacia Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top